2
www.nanochipxl.com Infection Control Panel SCREEN, ISOLATE, PROTECT Savyon Diagnostics is now offering its revolutionary test panel for the detection of MRSA, VRE and KPC directly from swab samples using the NanoChip ® XL molecular microarray system, thus enabling medium-high throughput screening from sample to results on the same working day and with minimal hands-on time. MRSA, VRE, KPC

Infection Control Panel - Clindia Beneluxnedcon.clindia.nl/_files/Brochures/Savyon/ICP-Brochure.pdf · Infection Control Panel SCREEN, ISOLATE, PROTECT Savyon Diagnostics is now offering

  • Upload
    others

  • View
    1

  • Download
    0

Embed Size (px)

Citation preview

Page 1: Infection Control Panel - Clindia Beneluxnedcon.clindia.nl/_files/Brochures/Savyon/ICP-Brochure.pdf · Infection Control Panel SCREEN, ISOLATE, PROTECT Savyon Diagnostics is now offering

www.nanochipxl.com

Infection Control PanelSCREEN, ISOLATE, PROTECT

Savyon Diagnostics is now offering its revolutionary test panel for the detection of MRSA, VRE and KPC directly from swab samples using the NanoChip®XL molecular microarray system, thus enabling medium-high throughput screening from sample to results on the same working day and with minimal hands-on time.

MRSA, VRE, KPC

Page 2: Infection Control Panel - Clindia Beneluxnedcon.clindia.nl/_files/Brochures/Savyon/ICP-Brochure.pdf · Infection Control Panel SCREEN, ISOLATE, PROTECT Savyon Diagnostics is now offering

Savyon Diagnostics Ltd. 3 Habosem St. Ashdod 77610, Israel, Tel.: 972 8 8562920, Fax: 972 8 8523176, Email: [email protected]

www.nanochipxl.comwww.savyondiagnostics.com

3520

- 0

1- 1

0/11

NanoChip is a registered trademarks of Gamida B.V, The Netherlands.The cartridge and NanoChip 400 system and their use may be covered by one or more of following U.S. Patents or Applications: 5,605,662; 5,929,208; 6,017,696; 6,238,624; 5,632,957; 6,582,660; 5,849,486; 6,245,508; 6,048,690; 6,051,380; 6,518,022; 2003/0190632; 5,965,452; 6,258,606; 6,682,936; 6,687,048; 2002/0131899A1; 2004/0149582A1; 6,099,803; 6,726,880; 6,225,059; 6,068,818; 6,540,961; 6,254,827; 6,315,953; 6,821,729; 6,331,274; US-2004-0038420-A1; 6,306,348; 6,524,517; 6,303,082; 6,838,053; 2005/0158451A1; 6,960,298; 2005/0164283A1; 6,207,373; 6,395,493; 6,753,148; 6,468,742; 2003/0073122; 6,379,897; 6,492,122.

Please note: Purchase of this instrument conveys a limited non-transferable immunity from suit for the purchaser›s own human in vitro diagnostics other than internal research and development and applied fields under non-real-time thermal cycler patents of Applied Biosystems LLC

Methicillin-Resistant Staphylococcus aureus (MRSA), Vancomycin-Resistant Enterococci (VRE) and Carbapenemase producing Klebsiella pneumoniae (KPC) colonization in hospital admitted patients is the leading cause for Hospital Acquired Infections (HAI). It is now evident that HAI can be widely prevented through screening of patients before or during hospital admission and proper patient isolation and management.

Molecular Targets

# Pathogen Gene Relevance

1 S. aureus spa & nuc

Detect & differentiate between S.aureus and other staphylococcal strains. (complementary markers)

2 Methicillin resistant bacteria

mecA Methicillin resistance marker

3 S.aureus SCCmec Confirmation of MRSA

4 Vancomycin resistant bacteria

vanA & vanB

Vancomycin resistance marker

5 Enterococci ddlEFM & ddlEFS

Enterococcal markers for E.faecium & E.faecalis

6 K.pneumoniae phoA K.pneumoniae marker

7 Carbapenamase producing bacteria

bla KPC Carbapenemase marker

Legend: MRSA: Methicillin Resistant S. aureus MSSA: Methicillin Sensitive S. aureus VRE: Vancomycin Resistant Enterococci VSE: Vancomycin Sensitive Enterococci KPC: Carbapenemase Producing Klebsiella pneumoniae KP: Klebsiella pneumoniae HAI: Hospital Acquired Infections